A common take on Intercept Pharmaceuticals Inc.’s obeticholic acid (OCA) status as the likely first-to-market drug for non-alcoholic steatohepatitis (NASH) is that the drug will have a safety and tolerability profile that may cause clinicians and patients to not want to use it or to abandon it at the first sign of a better treatment option. Intercept presented data at the 2019 American Association for the Study of Liver Diseases meeting in Boston that it thinks shows that to be a lesser concern.
The New York-based firm presented data on 10 November indicating that patient-reported outcomes show pruritus may not be as critical an issue for NASH patients as key opinion leaders think
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?